Ovarian Cancer

Pivotal Trial Completed, Primary Analysis Underway

Published in Vaccine Weekly, October 3rd, 2001

AltaRex Corp. (AXO.TO) announced that it has reached a major milestone in its OvaRex clinical development program - the completion for primary analysis of its designated pivotal 345-patient OvaRex trial.

Primary results from the trial will form the foundation of the Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for marketing approval of OvaRex monoclonal antibody (MAb). Submission of the BLA is expected by year end 2001 or early in 2002, assuming the timely scale-up of cell culture manufacturing to establish product comparability.

With the patient treatment now complete for this lead trial, an Endpoint...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-10-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry